Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Identify smart fund options for retirement diversification, focusing on balance, risk management, and practical allocation ideas for real-world use.
24,189 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
A founder sold a meaningful chunk of stock, but does that signal trouble or a routine liquidity move? This article br...
A high-profile insider sale puts Credit Acceptance and its subprime finance niche in the spotlight. This piece breaks...
Discover how Claros Mortgage Trust CMTG generates income, navigates rate risk, and positions its portfolio for the ne...
A notable fund boosted its Hexcel stake to roughly 23% of its portfolio after a $7.5 million purchase, sending the st...
When an executive at Century Aluminum sells millions in stock, investors take notice. This article breaks down what t...
Robinhood has evolved from a simple trading app to a platform with broader fintech ambitions. This article explores p...
Insider moves can ripple through biotech stocks. This piece breaks down recent tarsus pharma stock insider activity, ...
When geopolitics collide with global manufacturing, one top EV maker shows how to turn risk into growth. This story d...
A top tech entrepreneur’s possible pivot toward natural gas could ripple through energy markets. This guide breaks do...
A notable fund recently reported a substantial exit in a popular beauty stock. We break down what this move could sig...
Huron's latest revenue milestone grabbed headlines, but a large fund still trimmed its position. This article breaks ...